Connect your AI

Intellia Therapeutics NTLA Earnings yield

Earnings yield at other companies

Ionis PharmaceuticalsIONS

-2.6%-1.1pp

ALN

Alnylam PharmaceuticalsALNY

1.1%+0.8pp

CRISPR TherapeuticsCRSP

-12.5%-0.7pp

Beam TherapeuticsBEAM

-16.9%—

Iovance Biotherapeutics, Inc.IOVA

-24.5%-5.5pp

Viridian Therapeutics, Inc.VRDN

-18%-4.7pp

Other financials

Income statement

Revenue$15.0M-9.5%

Operating income-$100.5M+16.8%

Net income-$96.2M+15.8%

EPS (diluted)-$0.81+26.4%

Balance sheet

Cash & equivalents$134.7M+6.2%

Total debt$80.5M-32.5%

Total equity$620.9M-20.4%

Total assets$758.8M-23.1%

Cash flow

Operating cash flow-$117.3M+21.2%

CapEx$79.0K-89.3%

Free cash flow-$117.4M+21.5%

Valuation

Market cap$2.13B+106%

Enterprise value$2.08B+100%

P/S32.2×+9.5×

Profitability

Operating margin-636.6%-202pp

Net margin-597%-194pp

FCF margin-550.2%-140pp

Returns & leverage

Return on equity-56.3%-1.5pp

Debt / equity0.1×0.0×

Current ratio6.1×+1.2×

Where this comes from

Calculated from Intellia Therapeutics’s reported figures.

net income/market cap=-26.1%

Based on trailing twelve months.

The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Intellia Therapeutics's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Intellia Therapeutics's earnings yield?: Intellia Therapeutics (NTLA) reported earnings yield of -26.1% in Q1 2026.
How has Intellia Therapeutics's earnings yield changed year-over-year?: Intellia Therapeutics's earnings yield increased by 63.5% year-over-year, from -71.5% to -26.1%.
What is the long-term trend for Intellia Therapeutics's earnings yield?: Over 5 years (2020 to 2025), Intellia Therapeutics's earnings yield has grown at a 64.2% compound annual growth rate (CAGR), from -3.3% to -39.6%.
What does earnings yield mean?: Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.